Emerging of HIV drug resistance: Epidemiology, diagnosis, treatment and prevention

Current HIV Research

Volumn 7, Issue 3, 2009, Pages 273-278

  Kiertiburanakul, Sasisopin ^a   Sungkanuparph, Somnuek ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

AIDS; Antiretroviral therapy; Epidemiology; HIV; Resistance

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DARUNAVIR; ENFUVIRTIDE; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INTEGRASE INHIBITOR; MARAVIROC; NEVIRAPINE; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIPRANAVIR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL RESISTANCE; CD4 LYMPHOCYTE COUNT; DRUG MECHANISM; DRUG TREATMENT FAILURE; EARLY DIAGNOSIS; GENE SEQUENCE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAUTERINE INFECTION; PATHOGENESIS; PATIENT COMPLIANCE; REVIEW; SAFE SEX; SINGLE DRUG DOSE; VIRUS GENOME; CASE MANAGEMENT; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS; MICROBIOLOGICAL EXAMINATION; TREATMENT FAILURE; VIROLOGY; VIRUS LOAD;

ANTI-HIV AGENTS; CASE MANAGEMENT; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; TREATMENT FAILURE; VIRAL LOAD;

EID: 67649101424     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016209788347976     Document Type: Review

References (82)

1. UNAIDS and World Health Organization. AIDS Epidemic Update 2007. (http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf). Accessed 1 August 2008.
2. UNAIDS and World Health Organization. 2006 Report on the global AIDS epidemic. (http://www.unaids.org/en/KnowledgeCentre/HIVData/ GlobalReport/). Accessed 3 April 2008.
3. Guidelines for the use of antiretroviral agents in HIV-1-Infected adults and adolescents. U.S. Department of Health and Human Services (DHHS). January 29, 2008. (http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf). Accessed 1 August 2008.
4. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352: 1725-30.
5. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS trial: Italy, The Netherlands, Canada and Australia study. JAMA 1998; 279: 930-7.
6. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
7. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. JAMA 2006; 14: 827-43.
8. del Rio C. Current concepts in antiretroviral therapy failure. Top HIV Med 2006; 14: 102-6.
9. Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 1999; 13: 1873-80.
10. Yamashita TE, Phair JP, Muñoz A, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001; 15: 735-46.
11. Waters L, Nelson M. Why do patients fail HIV therapy? Int J Clin Pract 2007; 61: 983-90.
12. Gallant JE. Antiretroviral drug resistance and resistance testing. Top HIV Med 2006; 13: 138-42.
13. Kuritzkes DR. Preventing and managing antiretroviral drug resistance. AIDS Patient Care STDS 2004; 18: 259-73.
14. Division of HIV/AIDS Epidemiology and Surveillance, National HIV and Retrovirology Laboratories, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada, Health Canada. HIV-1 strain and primary drug resistance in Canada. Surveillance report to June 30, 2001. (http://www.phac-aspc.gc.ca/publicat/hiv1-vih1/pdf/ hiv-1-strain-01-e.pdf). Accessed 3 April 2008.
15. The International Consultation on Monitoring the Emergence of Antiretroviral Resistance sponsored by WHO, UNAIDS and ISS (October, 2000). (http://www.who.int/csr/resources/publications/drugresist/ WHO_CDS_CSR_DRS_2001_11/en/). Accessed 12 April 2008.
16. Geretti AM. Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis 2007; 20: 22-32.
17. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-94.
18. Sax PE, Islam R, Walensky RP, et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005; 41: 1316-23.
19. Corvasce S, Violin M, Romano L, et al. Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters. Antivir Ther 2006; 11: 329-34.
20. Fox JM, Fidler S, Weber J. Resistance to HIV drugs in UK may be lower in some areas. BMJ 2006; 332: 179-80.
21. Booth CL, Garcia-Diaz AM, Youle MS, Johnson MA, Phillips A, Geretti AM. Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother 2007; 59: 517-24.
22. Oette M, Kaiser R, Daumer M, et al. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 2006; 41: 573-81.
23. Shet A, Berry L, Mohri H, et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr 2006; 41: 439-46.
24. Jayaraman GC, Archibald CP, Kim J, et al. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr 2006; 42: 86-90.
25. Petroni A, Deluchi G, Pryluka D, et al. Update on primary HIV-1 resistance in Argentina: emergence of mutations conferring high-level resistance to nonnucleoside reverse transcriptase inhibitors in drug-naive patients. J Acquir Immune Defic Syndr 2006; 42: 506-10.
26. Rodrigues R, Scherer LC, Oliveira CM, et al. Low prevalence of primary antiretroviral resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed individuals from south Brazil. Virus Res 2006; 116: 201-7.
27. Maia Teixeira SL, Bastos FI, Hacker MA, Guimarães ML, Morgado MG. Trends in drug resistance mutations in antiretroviral-naive intravenous drug users of Rio de Janeiro. J Med Virol 2006; 78: 764-9.
28. Barreto CC, Nishyia A, Araujo LV, Ferreira JE, Busch MP, Sabino EC. Trends in antiretroviral drug resistance and clade distributions among HIV-1--infected blood donors in Sao Paulo, Brazil. J Acquir Immune Defic Syndr 2006; 41: 338-41.
29. Lama JR, Sanchez J, Suarez L, et al. Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance. J Acquir Immune Defic Syndr 2006; 42: 501-5.
30. Vessiere A, Nerrienet E, Kfutwah A, et al. HIV-1 pol gene polymorphism and antiretroviral resistance mutations in drug-naive pregnant women in Yaounde, Cameroon. J Acquir Immune Defic Syndr 2006; 42: 256-8.
31. Vergne L, Diagbouga S, Kouanfack C, et al. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antivir Ther 2006; 11: 575-9.
32. Koizumi Y, Ndembi N, Miyashita M, et al. Emergence of antiretroviral therapy resistance-associated primary mutations among drug-naive HIV-1-infected individuals in rural western Cameroon. J Acquir Immune Defic Syndr 2006; 43: 15-22.
33. Vidal N, Mulanga C, Bazepeo SE, et al. HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in the Democratic Republic of Congo (DRC). AIDS Res Hum Retroviruses 2006; 22: 202-6.
34. Agwale SM, Zeh C, Paxinos EE, et al. Genotypic and phenotypic analyses of human immunodeficiency virus type 1 in antiretroviral drug-naive Nigerian patients. AIDS Res Hum Retroviruses 2006; 22: 22-6.
35. Bezemer D, de Ronde A, Prins M, et al. Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load. Antivir Ther 2006; 11: 173-8.
36. Cohen J. Thailand's do-it-yourself therapy. Science 2003; 301: 1662.
37. Sukasem C, Churdboonchart V, Sirisidthi K, et al. Genotypic resistance mutations in treatment-naïve and treatment-experienced patients under widespread use of antiretroviral drugs in Thailand: implications for further epidemiologic surveillance. Jpn J Infect Dis 2007; 60: 284-9.
38. Apisarnthanarak A, Jirayasethpong T, Sa-nguansilp C, et al. Antiretroviral drug resistance among antiretroviral-naive persons with recent HIV infection in Thailand. HIV Med 2008; 9: 322-5.
39. Tee KK, Kamarulzaman A, Ng KP. Short communication: low prevalence of genotypic drug resistance mutations among antiretroviral-naive HIV type 1 patients in Malaysia. AIDS Res Hum Retroviruses 2006; 22: 121-4.
40. Apisarnthanarak A, Mundy LM. Antiretroviral drug resistance among antiretroviral-naive individuals with HIV infection of unknown duration in Thailand. Clin Infect Dis 2008; 46: 1630-1.
41. Gatanaga H, Ibe S, Matsuda M, et al. Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. Antiviral Res 2007; 75: 75-82.
42. Gonsalez CR, Alcalde R, Nishiya A, et al. Drug resistance among chronic HIV-1-infected patients naive for use of anti-retroviral therapy in Sao Paulo city. Virus Res 2007; 129: 87-90.
43. de Medeiros LB, Lacerda HR, Cavalcanti AM, de Albuquerque Mde F. Primary resistance of human immunodeficiency virus type 1 in a reference center in Recife, Pernambuco, Brazil. Mem Inst Oswaldo Cruz 2006; 101: 845-9.
44. Parienti JJ, Massari V, Descamps D, et al. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004; 38: 1311-6.
45. Phillips AN, Dunn D, Sabin C, et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005; 19: 487-94.
46. Phillips AN, Leen C, Wilson A, et al. Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet 2007; 370: 1923-8.
47. Ramadhani HO, Thielman NM, Landman KZ, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis 2007; 45: 1492-8.
48. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-6.
49. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-2.
50. Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science 1988; 242: 1171-3.
51. Gupta RK, Pillay D. HIV resistance and the developing world. Int J Antimicrob Agents 2007; 29: 510-7.
52. Richman DD. HIV chemotherapy. Nature 2001; 410: 995-1001.
53. Hoffmann - Rockstroh - Kamps HIV Medicine 2007. The 15th edition. (http://www.hivmedicine.com/hivmedicine2007.pdf). Accessed 1 April 2008.
54. De Mendoza C, Gallego O, Soriano V. Mechanisms of resistance to antiviral drugs-clinical implications. AIDS Rev 2002; 4: 64-82.
55. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15: 1951-7.
56. Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 2005; 192: 30-6.
57. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapinebased antiretroviral therapy. N Engl J Med 2004; 351: 229-40.
58. Gordon M, Graham N, Bland R, et al. Surveillance of resistance in KZN South Africa, including mother-infant pairs 6 weeks after single-dose NVP. Antivir Ther 2004; 9: S80.
59. Arrive E, Newell ML, Ekouevi DK, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007; 36: 1009-21.
60. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356: 135-47.
61. Coovadia A, Marais B, Abrams E, et al. Virologic responses to NNRTI treatment among women who took single-dose nevirapine 18 to 36 months earlier. Presented at the 13th Conference on Retroviruses and Opportunistic Infections, February 2006, Denver, CO. [abstract]
62. McConnell MS, Stringer JS, Kourtis AP, Weidle PJ, Eshleman SH. Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter? Am J Obstet Gynecol 2007; 197: S56-63.
63. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37: 113-28.
64. Hecht FM, Grant RM. Resistance testing in drug-naive HIV-infected patients: is it time? Clin Infect Dis 2005; 41: 1324-5.
65. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 2006; 14: 125-30.
66. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14: F83-93.
67. Barbour JD, Wrin T, Grant RM, et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol 2002; 76: 11104-12.
68. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretro-viral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44: 447-52.
69. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Rapid CD4 decline after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy in a resource-limited setting. AIDS Res Ther 2007; 4: 26.
70. Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349: 837-46.
71. Knoll BM, Vento S, Temesgen Z. Etravirine. Drugs Today (Barc) 2008; 44: 23-33.
72. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006; 368: 466-75.
73. El-Atrouni WI, Temesgen Z. Darunavir. Drugs Today (Barc) 2007; 43: 671-9.
74. Bennett DE. The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world. Curr Opin Infect Dis 2006; 19: 607-14.
75. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS 2003; 17: 169-77.
76. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999; 282: 1135-41.
77. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
78. Friedland GH, Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 1999; 13: S61-72.
79. Fischl MA. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection. AIDS 1999; 13: S49-S59.
80. Oette M, Kaiser R, Daumer M, et al. Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany. Eur J Med Res 2004; 9: 273-8.
81. Chaix ML, Ekouevi DK, Rouet F, et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J Infect Dis 2006; 193: 482-7.
82. McIntyre JA, Martinson N, Gray GE. Addition of short course Combivir to single dose Viramune for the prevention of mother to child transmission of HIV-1 can significantly decrease the subsequent development of maternal and pediatric NNRTI-resistant virus. Presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, July 2005, Rio de Janeiro, Brazil. [abstract TuFo0204].